Video | 08 November 2023 Access to insulin pens - Siwar DIABETES MSF has transitioned all patients with type 1 diabetes in our clinics in Lebanon from vials to insulin pens. Here are the stories from patients and staff about how the move has improved both medical outcomes and patients’ quality of life. Read, watch, share Filter by - Any -BlogFeature storyIssue briefLetterPress releaseReport seriesResearch articleStatementTechnical briefVideo Photo Credit: Bafana Ngwenya/MSF 12 June 2025 Diabetes MSF welcomes Novo Nordisk’s commitment to supply South Africa with analogue insulin pens, but the price must come down to $1 per pen 3 min Video Video | 21 November 2024 Diabetes Ghassan’s story: Struggling to access insulin while on a journey to seek asylum in Europe Video Video | 21 November 2024 Diabetes Anis’s story: Fleeing with a newborn while dealing with diabetes Video Video | 21 November 2024 Diabetes Amina’s story: Fleeing from violence with a son with diabetes 1 min Photo credit: Carmen Yahchouchi/MSF Letter Letter | 11 November 2024 Diabetes MSF comments on replies from Eli Lilly, Novo Nordisk and Sanofi on access to insulin Letter | 11 November 2024 Diabetes Comments on Sanofi’s reply letter on access to insulin Letter | 11 November 2024 Diabetes Comments on Novo Nordisk’s reply letter on access to insulin Letter | 11 November 2024 Diabetes Comments on Eli Lilly’s reply letter on access to insulin Load More
Photo Credit: Bafana Ngwenya/MSF 12 June 2025 Diabetes MSF welcomes Novo Nordisk’s commitment to supply South Africa with analogue insulin pens, but the price must come down to $1 per pen 3 min
Video Video | 21 November 2024 Diabetes Ghassan’s story: Struggling to access insulin while on a journey to seek asylum in Europe
Video Video | 21 November 2024 Diabetes Anis’s story: Fleeing with a newborn while dealing with diabetes
Video Video | 21 November 2024 Diabetes Amina’s story: Fleeing from violence with a son with diabetes 1 min
Photo credit: Carmen Yahchouchi/MSF Letter Letter | 11 November 2024 Diabetes MSF comments on replies from Eli Lilly, Novo Nordisk and Sanofi on access to insulin